---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-185324"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2022-06-30T23:59:59+00:00"
generated_at: "2026-06-24T21:57:32.608128+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience receives termination notice from EOC Pharma for FYARRO license in Greater China

## Summary
- EOC Pharma terminated FYARRO license agreement for Greater China effective June 27, 2022.
- Aadi disputes EOC's allegations of material breach; believes termination is for convenience.
- Aadi had received $14M upfront and $1M milestone; lost potential $257M in milestones and royalties.
- No further payments from EOC expected; Aadi loses exclusive development/commercialization partner for China.

## SEC filing metadata
- accession: 0001193125-22-185324
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2022-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312522185324/0001193125-22-185324-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312522185324/d360965d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-185324
- JSON: https://secwatch.observer/filing/0001193125-22-185324.json
- Plain text: https://secwatch.observer/filing/0001193125-22-185324.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.